Eli Lilly to buy cancer-focused Point Biopharma for $1.4 billion

mediabest
FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021. Picture taken March 5, 2021. REUTERS/Mike Segar/File Photo

(Reuters) -Eli Lilly and Co will buy cancer therapy developer Point Biopharma Global for $1.4 billion, the companies said on Tuesday.

Lilly has offered $12.50 per Point Biopharma share held, representing a premium of about 87% to the stock’s last close.

Point Biopharma’s shares soared 84% in premarket trading.

The companies expect the deal to close by the end of 2023.

Source: Read Full Article

Related posts:
  1. Intermittent fasting: In a 24/7 food culture, periodic fasting gains followers
  2. Celebrities Who Opened Up About Having Abortions
  3. Machine-learning improves the prediction of stroke recovery
  4. Covid’s ‘Silver Lining’: Research Breakthroughs for Chronic Disease, Cancer, and the Common Flu
  5. PIK3CA Mutation Predicts Worse Outcomes in HER2+ Breast Cancer